Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo

Background: Anlotinib is a highly potent multi-target tyrosine kinase inhibitor. Accumulating evidence suggests that anlotinib exhibits effective anti-tumor activity against various cancer subtypes. However, the effects of anlotinib against cisplatin-resistant (CIS) ovarian cancer (OC) are yet to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yurou, Li, Xinyu, Qi, Yue, Zhao, Jianguo, Zhang, Wenwen, Qu, Pengpeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785832/
https://www.ncbi.nlm.nih.gov/pubmed/36558006
http://dx.doi.org/10.3390/molecules27248873

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785832/
https://www.ncbi.nlm.nih.gov/pubmed/36558006
http://dx.doi.org/10.3390/molecules27248873

Ejemplares similares